France easing up on GMOs
Schofield 6-1 (Ian Schofield, BA in Modern Language – French and Italian - @ Uni of Bath, Reporter/Deputy Editor @ Scrip World Pharmaceutical News/Informa, “France Eases Procedures For GMO-Containing Medicines”, https://pink.pharmaintelligence.informa.com/PS146261/France-Eases-Procedures-For-GMO-Containing-Medicines#:~:text=The%20French%20medicines%20agency%2C%20ANSM,available%20under%20early%20access%20protocols.)LR
The French medicines agency, ANSM, has implemented a new, simplified procedure for medicines containing genetically modified organisms, including gene therapies and certain vaccines, that are to be tested in clinical trials or made available under early access protocols. As of 1 June, all applications for the "contained use" of GMO-containing products in clinical trials must be made to ANSM, as must requests for "deliberate release" of such products in the context of early and compassionate access to advanced therapy medicinal products (ATMPs) prepared on an ad hoc basis for gene therapy. Under EU rules, the individual member states are responsible for authorizing clinical trials of investigational medicinal products containing or consisting of GMOs, which must comply with the EU legislation on the deliberate release of GMOs into the environment or their contained use. In France, the transfer of GMO responsibilities to ANSM comes in the wake of new rules in January this year. These rules were outlined in a decree of 30 December 2021 that updated the processes for evaluating biotechnologies and simplified the procedures relating to the uses of GMOS presenting a "zero or negligible risk." From today, trial sponsors can now use a new centralized "simplified procedures" platform for submitting applications to ANSM for GMO trials, which can be accessed via the ANSM website. The submission must be accompanied by a technical dossier and a list of the trial sites. For deliberate release purposes, companies must file an application for authorization, again using the simplified procedure platform and including a technical dossier. The content of the dossier, which was set out in a decree of 25 January 2022, should include an assessment of the potential risks posed to public health and the environment, according to ANSM. Simplified And Full Dossiers As of 1 June, a simplified dossier is required for clinical trials of genetically modified human cells, adeno-associated viral vectors, and authorized medicines. A full dossier is required for any other type of viral vector. There are common application forms for each of these types of trials. For genetically modified human cells, for example, the form should be used for human cells genetically modified by means of retro/lentiviral vectors, including genome edited cells. In such cases, the applicant must show that there is no risk of formation of replication competent virus, and that residual infectious retro/lentiviral vector particles have been reduced to negligible concentrations in the finished product, or there is negligible risk associated with the presence of residual infectious viral vector particles in the finished product. The form should also be used for human cells genetically modified by means of adeno-associated viral vectors, including genome edited cells, where the applicant demonstrates that there is no risk of formation of replication competent virus; and for human cells genetically modified without viral vectors, including genome edited cells. For already authorized GMO-containing medicines to be used in a trial, the information submitted should include the date of EU marketing authorization, the latest update of the summary of product characteristics, and any new risks identified and risk-minimization measures implemented. The applicant should also explain why it considers that the conduct of the proposed trial "does not entail risks other than those already assessed in the context of the marketing authorization procedure." New Advisory Body Responsibility for trials of GMO-containing medicines previously lay with the research ministry. While ANSM has now taken over this role, the research ministry has set up a new expert advisory committee on the contained use of GMOs. ANSM can ask this committee for an opinion on matters relating to contained use, while for deliberate release it can consult ANSES, the French agency for food and environmental and occupational health and safety.